MiRNAs in breast cancer: Ready for real time?

Pharmacogenomics

Volumn 13, Issue 6, 2012, Pages 709-719

  Krell, Jonathan ^a   Frampton, Adam E ^a   Jacob, Jimmy ^a   Castellano, Leandro ^a   Stebbing, Justin ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

biomarkers; breast cancer; miRNAs; pathogenesis; therapeutics

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA; MICRORNA 122; MICRORNA 16; MICRORNA ANTIBODY; MIRAVIRSEN; PROGESTERONE RECEPTOR; RNA ANTIBODY; UNCLASSIFIED DRUG;

APOPTOSIS; BONE METASTASIS; BREAST CANCER; CANCER GENE THERAPY; CANCER SURVIVAL; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; MELANOMA; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PATHOGENESIS; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859979625     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.15     Document Type: Review

References (117)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004).
2. nFirst study to identify and describe miRNA role and function.
3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 136(2), 215-233 (2009).
4. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39(Database issue), D152-D157 (2011).
5. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101(9), 2999-3004 (2004). (Pubitemid 38327724)
6. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 136(4), 586-591 (2009).
7. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002). (Pubitemid 35403967)
8. nFirst study to show a link between miRNAs and cancer.
9. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 26(19), 2799-2803 (2007). (Pubitemid 46663837)
10. Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14(11), 2348-2360 (2008).
11. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005). (Pubitemid 41161233)
12. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37(8), 2584-2595 (2009).
13. Yang Y, Chaerkady R, Beer MA, Mendell JT, Pandey A. Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics 9(5), 1374-1384 (2009).
14. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282(19), 14328-14336 (2007). (Pubitemid 47100416)
15. Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6), 1109-1123 (2007). (Pubitemid 350235025)
16. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005). (Pubitemid 40343076)
17. Zhao Y, Deng C, Wang J et al. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 127(1), 69-80 (2011).
18. Spizzo R, Nicoloso MS, Lupini L et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 17(2), 246-254 (2010).
19. Kim K, Chadalapaka G, Lee SO et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 31(8), 1034-1044 (2012).
20. Kong W, He L, Coppola M et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 285(23), 17869-17879 (2010).
21. Shimono Y, Zabala M, Cho RW et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138(3), 592-603 (2009).
22. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res. 67(22), 11001-11011 (2007). (Pubitemid 350145930)
23. Castellano L, Giamas G, Jacob J et al. The estrogen receptor-alpha- induced microRNA signature regulates itself and its transcriptional response. Proc. Natl Acad. Sci. USA 106(37), 15732-15737 (2009).
24. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 127(4), 679-695 (2006). (Pubitemid 44781029)
25. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2(6), 442-454 (2002).
26. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 3(6), 453-458 (2003). (Pubitemid 37328849)
27. Ma L, Weinberg RA. Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet. 24(9), 448-456 (2008).
28. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat. Rev. Cancer 9(4), 293-302 (2009).
29. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163), 682-688 (2007). (Pubitemid 47552092)
30. Ma L, Young J, Prabhala H et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12(3), 247-256 (2010).
31. Tavazoie SF, Alarcon C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175), 147-152 (2008).
32. Valastyan S, Reinhardt F, Benaich N et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137(6), 1032-1046 (2009).
33. Huang Q, Gumireddy K, Schrier M et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 10(2), 202-210 (2008). (Pubitemid 351194050)
34. Lujambio A, Calin GA, Villanueva A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA 105(36), 13556-13561 (2008).
35. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006). (Pubitemid 43357945)
36. Gee GV, Koestler DC, Christensen BC et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int. J. Cancer 127(12), 2859-2869 (2010).
37. Fassan M, Sachsenmeir K, Rugge M, Baffa R. Role of miRNA in distinguishing primary brain tumors from secondary tumors metastatic to the brain. Front. Biosci. (Schol. Ed.) 3, 970-979 (2011).
38. Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17), 2537-2545 (2006).
39. Roldo C, Missiaglia E, Hagan JP et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 24(29), 4677-4684 (2006). (Pubitemid 46630931)
40. Mattie MD, Benz CC, Bowers J et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006).
41. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
42. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006). (Pubitemid 43271657)
43. Liu J, Gao J, Du Y et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int. J. Cancer doi:10.1002/ijc.26422 (2011) (Epub ahead of print).
44. Zheng D, Haddadin S, Wang Y et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4(6), 575-586 (2011).
45. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2, 89 (2009).
46. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12(6), R90 (2010).
47. Heneghan HM, Miller N, Kerin MJ. Circulating microRNAs: promising breast cancer biomarkers. Breast Cancer Res. 13(1), 402; author reply 403 (2011).
48. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 5(10), e13735 (2010).
49. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 251(3), 499-505 (2010).
50. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev. Mol. Diagn. 11(3), 259-275 (2011).
51. Shigehara K, Yokomuro S, Ishibashi O et al. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS ONE 6(8), e23584 (2011).
52. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127(12), 2870-2878 (2010).
53. Ahmed FE, Jeffries CD, Vos PW et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 6(5), 281-295 (2009).
54. Rask L, Balslev E, Jorgensen S et al. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. Acta Pathol. Microbiol. Immunol. Scand. 119(10), 663-673 (2011).
55. Sempere LF, Preis M, Yezefski T et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. Clin. Cancer Res. 16(16), 4246-4255 (2010).
56. Munding JB, Adai AT, Maghnouj A et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int. J. Cancer doi:10.1002/ijc.26466 (2011) (Epub ahead of print).
57. Bockmeyer CL, Jonigk D, Kreipe H, Lehmann U. MicroRNA profiling using RNA from microdissected immunostained tissue. Methods Mol. Biol. 755, 85-94 (2011).
58. Buffa FM, Camps C, Winchester L et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. 71(17), 5635-5645 (2011).
59. Sempere LF, Christensen M, Silahtaroglu A et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 67(24), 11612-11620 (2007).
60. Cronin M, Sangli C, Liu ML et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53(6), 1084-1091 (2007). (Pubitemid 46867525)
61. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002). (Pubitemid 34130608)
62. Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13(1), 48-57 (2008).
63. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4), 425-436 (2008). (Pubitemid 351185951)
64. Schetter AJ, Nguyen GH, Bowman ED et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin. Cancer Res. 15(18), 5878-5887 (2009).
65. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 12(12), 2171-2176 (2008).
66. Huang S, He X. The role of microRNAs in liver cancer progression. Br. J. Cancer 104(2), 235-240 (2011).
67. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361(15), 1437-1447 (2009).
68. Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. Hepatology 52(3), 1164-1166 (2010).
69. Rothé F, Ignatiadis M, Chaboteaux C et al. Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE 6(6), e20980 (2011).
70. Foekens JA, Sieuwerts AM, Smid M et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc. Natl Acad. Sci. USA 105(35), 13021-13026 (2008).
71. Camps C, Buffa FM, Colella S et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 14(5), 1340-1348 (2008). (Pubitemid 351413913)
72. Zhang Z, Sun H, Dai H et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8(17), 2756-2768 (2009).
73. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93(4), 387-391 (2005). (Pubitemid 43080010)
74. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38(7), e190-e199 (2009).
75. Hwang JH, Voortman J, Giovannetti E et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS ONE 5(5), e10630 (2010).
76. Giovannetti E, Funel N, Peters GJ et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70(11), 4528-4538 (2010).
77. Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68(2), 425-433 (2008). (Pubitemid 351380068)
78. Eitan R, Kushnir M, Lithwick-Yanai G et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol. Oncol. 114(2), 253-259 (2009).
79. Ferracin M, Zagatti B, Rizzotto L et al. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol. Cancer 9, 123 (2010).
80. Mei M, Ren Y, Zhou X et al. Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol. Cancer Res. Treat. 9(1), 77-86 (2010).
81. Liang Z, Wu H, Xia J et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 79(6), 817-824 (2010).
82. Kovalchuk O, Filkowski J, Meservy J et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 7(7), 2152-2159 (2008).
83. Jansen MP, Reijm EA, Sieuwerts AM et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res. Treat. doi:10.1007/s10549-011-1877-4 (2011) (Epub ahead of print).
84. Yeung ML, Jeang KT. MicroRNAs and cancer therapeutics. Pharm. Res. 28(12), 3043-3049 (2011).
85. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13(4), 431-456 (2007). (Pubitemid 46509424)
86. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 18(12), 1121-1126 (2011).
87. Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl. Res. 157(4), 216-225 (2011).
88. Song E, Lee SK, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9(3), 347-351 (2003). (Pubitemid 36362792)
89. Krützfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438(7068), 685-689 (2005).
90. Felicetti F, Errico MC, Bottero L et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 68(8), 2745-2754 (2008). (Pubitemid 351556272)
91. Gandellini P, Profumo V, Folini M, Zaffaroni N. MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin. Ther. Targets 15(3), 265-279 (2011).
92. Lanford RE, Hildebrandt-Eriksen ES, Petri A et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962), 198-201 (2010).
93. Haussecker D, Kay MA. miR-122 continues to blaze the trail for microRNA therapeutics. Mol. Ther. 18(2), 240-242 (2010).
94. nFirst example of a miRNA-based approach to therapy in humans entering early phase clinical trials.
95. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4(9), 721-726 (2007). (Pubitemid 47338166)
96. Gentner B, Schira G, Giustacchini A et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 6(1), 63-66 (2009).
97. Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with small molecules: from dream to reality. Clin. Pharmacol. Ther. 87(6), 754-758 (2010).
98. Davis ME, Zuckerman JE, Choi CH et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291), 1067-1070 (2010).
99. nSuccessful example of the use of miRNA-based therapeutic technologies being used in cancer patients in a Phase I study.
100. Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005-1017 (2009).
101. Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12(5), 329-340 (2011).
102. Trang P, Medina PP, Wiggins JF et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29(11), 1580-1587 (2010).
103. Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18(1), 181-187 (2010).
104. Andre F, McShane LM, Michiels S et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8(3), 171-176 (2011).
105. Jiang S, Zhang HW, Lu MH et al. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70(8), 3119-3127 (2010).
106. Xiang X, Zhuang X, Ju S et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 30(31), 3440-3453 (2011).
107. Kong W, Yang H, He L et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 28(22), 6773-6784 (2008).
108. Yan GR, Xu SH, Tan ZL, Liu L, He QY. Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. Proteomics 11(5), 912-920 (2011).
109. Sossey-Alaoui K, Downs-Kelly E, Das M, Izem L, Tubbs R, Plow EF. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int. J. Cancer 129(6), 1331-1343 (2011).
110. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res. 70(12), 5147-5154 (2010).
111. Qian P, Zuo Z, Wu Z et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 71(20), 6463-6474 (2011).
112. Zhao Y, Deng C, Lu W et al. Let-7 microRNAs induce tamoxifen sensitivity by down-regulation of estrogen receptor alpha signaling in breast cancer. Mol. Med. doi:10.2119/molmed.2010.00225 (2011) (Epub ahead of print).
113. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481(7380), 190-194 (2012).
114. Yoshimoto N, Toyama T, Takahashi S et al. Distinct expressions of microRNAs that directly target estrogen receptor alpha in human breast cancer. Breast Cancer Res. Treat. 130(1), 331-339 (2011).
115. Zhang Y, Yan LX, Wu QN et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 71(10), 3552-3562 (2011).
116. Li D, Zhao Y, Liu C et al. Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin. Cancer Res. 17(7), 1722-1730 (2011).
117. Zhang B, Liu XX, He JR et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 32(1), 2-9 (2011).